Virus Shows Promise for Deep Tissue Imaging/Monitoring and Treating Pancreatic Cancer
September 15, 2011
In a press release issued Thursday by the American Association for Cancer Research (AACR), researchers announced that Genelux Corporation’s vaccinia virus, GLV-1h153, shows promise as a potential treatment and non-invasive deep tissue imaging modality for pancreatic cancer. Specifically, researchers have found that the
The study is a collaboration between researchers at Memorial Sloan-Kettering Cancer Center in New York, N.Y., and at Genelux Corporation in San Diego, Calif. Study results were presented at the Second AACR International Conference on Frontiers in Basic Cancer Research, held Sept. 14-18, 2011, in San Francisco.
To view the complete AACR press release, click here